Pharmaceuticals

Imperial College London is a hive of activity in drug discovery and development. Imperial hosts some of the world’s leading scientists as well as the affiliation with Imperial NHS trust, one of the largest academic health systems in Europe.

Based on these cutting edge capabilities, ICON has a proven record in assisting pharmaceutical companies and CROs to develop successful, ground-breaking medicines.

Our consultants are key opinion leader physicians and globally renowned researchers, who are committed to translating their expertise into practice in order to push the boundaries of drug development.

We have helped clients solve a range of problems:

 

SCIENTIFIC AND REGULATORY ADVICE AND PROTOCOL ASSISTANCE

Our academics have offered scientific, regulatory advice as well as assistance with clinical trial protocols in all therapeutic classes including rare diseases.`

 

PRE-CLINICAL DEVELOPMENT

Validated disease models in multiple therapeutic areas, high throughput screening, assays, pre-clinical species PK/PD, imaging, medicinal chemistry, structural synthesis pathways and lead optimisation strategy.

 

VACCINE DEVELOPMENT

Identification of antigens, reverse vaccinology, vaccine challenge tests for RSV, malaria and influenza.

 

MOLECULAR DIAGNOSTICS UNIT (MDU)

The CPA-accredited Molecular Diagnostic Unit (MDU) provides fast, accurate diagnostic tests for the management of infectious and genetic diseases using latest technology, including next generation sequencing and UPLC. Through ongoing research and development of new diagnostic methods it strives to remain ahead of the field in diagnostic testing and clinical monitoring.

The MDU supports the HIV and HTLV trials of the Clinical Trials Centre and patient management for The National Centre for Human Retrovirology and Imperial College Healthcare Trust.

Work to date has been centred on HIV, hepatitis viruses and sexually transmitted infections – but the clinical requirements of other clients can be catered for, click for more details

 

 

ACCESS TO FACILITIES

Genomics, biomarker discovery, high throughput mass spec, NMR, X-ray crystallography, advanced PET, advanced MRI, functional MRI and quantitative image analysis using AI.

Whether you need help with pre/clinical development or access to cutting edge validated assays and disease models, we can find the right people to help you solve a problem flexibly and responsively.

Advisory services

Product design, research methods, data analysis, technology evaluation for investment, technological innovation, patent evaluation, prototype and protocol development, policy, cyber security and more. Assisting museums, writers, film makers and artists to ensure creations scientifically sound.

Expert insight

Membership of Scientific Advisory Boards and Technical Panels, advice and guidance on drug development programmes, thought leadership, conference speakers, literature reviews and provision of foresight.

Analysis and testing

Use of the world-class specialist facilities and technicians at Imperial for projects ranging from aerodynamic measurements and medical imaging to structural testing and analysis.

Our consultants are world-leading experts in their field, committed to on-going research.

Who to contact:

Poh-Choo Pang

Poh-Choo Pang

Engagement Manager

For Clinical Sciences, Medicine, Chemistry, Bio-Sciences, Biochemistry, Bio-tech, Ecology, Microbiology, Physics

Tel: +44 (0)20 7594 6557

Email me

All areas of expertise:

Related Insights

Modelling an unprecedented pandemic

Modelling an unprecedented pandemic

During the COVID-19 pandemic, scientists tried to understand the behaviour of the tiny virus particles as well as their effects on very large numbers of human hosts, attempting to bridge these two worlds coherently. But ‘the science’ isn’t a singular entity: it’s highly collaborative, consensus based – and yes, subject to uncertainty. read more

Decision-making under uncertainty

Decision-making under uncertainty

Decision-making under uncertainty - Read how Imperial academics are helping companies maximise performance even in highly uncertain times. read more

Digital transformation

Digital transformation

Some think of business as usual, replacing physical tasks with digital alternatives. Others envisage a more profound change, with new products or services made possible by digital technologies. read more

Related case studies

Global adoption and regulation of electronic medical records

Global adoption and regulation of electronic medical records

Our consultants shared their expertise in clinical medicine to help IMS Health to assess the adoption, governance and regulatory landscape of electronic medical records (EMR) at different levels of healthcare systems around the world. read more

Scottish health service delivery and performance

Scottish health service delivery and performance

Our consultants shared their expertise in acute medicine and experience of working for governmental organisations and the NHS to help NHS Scotland and the Scottish Government to improve efficiency and quality in the Scottish health service. read more

Management of pests and vectors of disease

Management of pests and vectors of disease

Helping small-holder farmers with cost-effective techniques to manage pests and vectors of disease, reducing the use of chemical pesticides and promoting the efficiency of natural processes. read more

Latest news

Prof David Nethercot appointed as assessor to assist Grenfell Tower Inquiry Chairman

Prof David Nethercot appointed as assessor to assist Grenfell Tower Inquiry Chairman

David Nethercot, Emeritus Professor of Civil Engineering, has been appointed by the Chairman of the Grenfell Tower Inquiry to assist him in considering technical issues relating to the design and construction of the building and its refurbishment. read more

SMEs report university partnership success

SMEs report university partnership success

Partnerships between small firms and universities can drive innovation and growth, reveals new research, which was released as part of Universities Week 2011. read more

Groundbreaking analysis reveals a fully flexible energy system could cut the cost of reaching net zero by up to £16.7bn a year in 2050

Groundbreaking analysis reveals a fully flexible energy system could cut the cost of reaching net zero by up to £16.7bn a year in 2050

Analysis led by the Carbon Trust and Prof Strbac and supported by Bryt Energy, EDF, Greater London Authority, IGEM, Kiwi Power, Low Carbon Contracts Company, SBM Offshore, SP Energy Networks, Statera Energy, Scottish and Southern Electricity Networks (SSEN), UK Power Networks and Western Power Distribution. read more